Taysha Gene Therapies (NASDAQ: TSHA) is a clinical-stage gene therapy company developing treatments for rare neurological diseases. It has no approved products and has never generated revenue from product sales as of the 10-K filed March 19, 2026. Operations are funded entirely through equity financings and debt, having raised $961.0 million in gross proceeds from equity financings since inception, including pre-IPO private placements, its IPO, and subsequent public and private securities offerings. The company holds an exclusive, worldwide, royalty-free license from UT Southwestern Medical Center and an exclusive, worldwide, royalty-bearing license from Abeona Therapeutics covering certain gene therapy programs. Net losses were $109.0 million for the year ended December 31, 2025 and $89.3 million for the year ended December 31, 2024, with an accumulated deficit of $711.3 million as of December 31, 2025. All product candidates remain in clinical or preclinical development.

Revenue model

Taysha generates no product revenue. Operations are financed through equity issuances, at-the-market offerings, and a loan agreement with Trinity Capital. The company previously held a strategic option and securities purchase agreement with Audentes Therapeutics (d/b/a Astellas Gene Therapy).

Products and services

All product candidates are in clinical or preclinical development as of the 10-K filed March 19, 2026. The pipeline is built on gene therapy programs, including programs licensed from UT Southwestern Medical Center and a Rett syndrome program licensed from Abeona Therapeutics. No products are approved for commercialization.

Customers and end markets

No commercial customers. End markets are patients with rare neurological diseases. Products are in clinical or preclinical development with no approved therapies as of the 10-K filed March 19, 2026.

Value-chain role

Clinical-stage drug developer. Relies on contract manufacturing organizations for cGMP material production for clinical trials. Licenses intellectual property from academic and industry partners including UT Southwestern Medical Center and Abeona Therapeutics.

Geographic exposure

Incorporated and headquartered in the United States. Licenses are described as worldwide in scope. No commercial geographic revenue mix is disclosed given pre-revenue status.

Source: SEC 10-K, filed 2026-03-19

Industry: Biological Products, (No Diagnostic Substances) Peers: Mink Therapeutics Inc Black Diamond Therapeutics Inc Harvard Apparatus Regenerative Technology Inc Apexigen, Inc. iBio Inc LUMOS PHARMA, INC. Dianthus Therapeutics Inc Spero Therapeutics Inc